Eric Rubin, M.D.
Vice President and Therapeutic Area Head, Oncology Early Development
Merck Research Laboratories
Dr. Rubin has focused on cancer drug development for over 20 years, initially as a faculty member at the Dana-Farber Cancer Institute in Boston, then as a senior leader of the Cancer Institute of New Jersey. His research efforts focused on mechanisms of resistance to DNA topoisomerase-targeting drugs and his laboratory cloned a novel topoisomerase I- and p53-interacting tumor suppressor gene, TOPORS. In 2008, Dr. Rubin was recruited to Merck & Co, Inc., as vice president, Oncology Clinical Research.
Dr. Rubin led the development of the anti-PD-1 antibody pembrolizumab, which was the first anti-PD-1 therapy approved in the U.S., and the identification of the significant activity of this antibody across several additional cancer types. In his current role he oversees oncology early development and translational research activities.
Dr. Rubin obtained his medical degree from the University of South Florida and completed residency at Yale-New Haven Hospital. He has authored over 100 original peer-reviewed publications and book chapters related to oncology translational research, clinical trials and drug development. He has served frequently as a member of National Cancer Institute and American Cancer Society study sections, as well as on program committees for the American Association of Cancer Research and the American Society of Clinical Oncology. In addition, he serves on several editorial boards and is a deputy editor for Clinical Cancer Research.